SCHEMBL9866779

SCHEMBL9866779

N=C(NCCCc1c[nH]cn1)NCCSCc1cccc2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2D6 P10635 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MCL1 Q07820 1/20 0.34
SSTR2 P30874 1/20 0.34
SSTR4 P31391 1/20 0.34
MTNR1A P48039 2/20 0.34
HSP90AB1 P08238 1/20 0.34
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
MAPT P10636 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180733 0.84 LMNA (0.37) CYP1A2SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL9866789 0.84 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2
SCHEMBL9866225 0.83 PSMB5 (0.46)
SCHEMBL9867267 0.83 LMNA (0.35) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2
SCHEMBL9876539 0.80 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2
SCHEMBL9866401 0.79 SMN1; SMN2 (0.44) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2
SCHEMBL7176944 0.79 SLC47A1 (0.32)
SCHEMBL9868517 0.79 KMT2A (0.42) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2
SCHEMBL9866034 0.79 ALDH1A1 (0.45) HPGDSMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL9865647 0.79 GAA (0.45) CYP1A2CYP2C9CYP2C19HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed
EP-0199845-B1 IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HEUMANN PHARMA GMBH & CO (DE) 1990-08-01 EP disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed